How big of a problem is this really?

Migraine affects roughly 1.16 billion people globally and is the third most disabling neurological condition on the planet, costing the US economy about $22 billion a year ($11B medical + $11B lost productivity, or ~$10,287 per patient annually).¹˒²˒³ The newest preventive class in anti-CGRP drugs like Aimovig, Emgality, Qulipta, and Nurtec generate ~$6.2B in annual revenue across seven approved drugs. But here's the catch: real-world data show 35-50% of patients don't get a meaningful response, and even after cycling through two or three different CGRP antibodies, 29-42% of those initial non-responders still don't respond.⁴˒⁵ That leaves roughly 1.0-1.8 million US patients who've failed the best modern medicine has to offer, with no validated next-mechanism drug in clinic.

So what's actually going wrong, and how do we fix it?

During a migraine attack, the trigeminovascular system releases two neuropeptides, CGRP and PACAP, onto cranial blood vessels, and both converge on opening ATP-sensitive potassium (KATP) channels in vascular smooth muscle, which dilates the vessels and propagates the attack.⁶ Blocking just CGRP fails half the patients because their attacks fire through PACAP or other parallel signals that hit the same downstream switch. The data here is unusually clean: when researchers in Copenhagen infused levcromakalim (a drug that opens the vascular Kir6.1/SUR2B subtype of this channel) into migraine patients, 16 out of 16 developed full migraine attacks, while healthy controls got only mild headache.⁷ Run the same experiment with NN414 (which opens the pancreatic version of the channel)? Zero migraines.⁸ Knock out the vascular channel in mouse smooth muscle? The mice are protected.⁹ Pharmacology, genetics, and human provocation all line up — this is the cleanest target validation in migraine pharmacology.

Can we actually build a drug for this, and is anyone doing it?

As of 2024, yes. A Vanderbilt team published VU0542270, the first selective inhibitor of vascular Kir6.1/SUR2B channels (>300x selective over the pancreatic version), with four additional backup chemotypes,¹⁰ and atomic-resolution cryo-EM structures of the channel were published in 2022, making structure-based drug design fully tractable.¹¹ There is zero clinical-stage competition on this target anywhere in the world. The economics work: positioned for the 1.05M US CGRP-refractory patients at $12,000/year and 20% peak penetration, you get ~$2.5B US peak revenue / ~$4.5B globally. This is Nurtec-tier in an uncontested market. Capital to reach the Phase 1 levcromakalim provocation proof-of-concept (the value inflection that doubles asset value) is approximately $60M. And the precedent for this playbook just paid out. Vertex's suzetrigine (a structurally-enabled Nav1.8 ion channel pain drug) was FDA-approved in January 2025 using essentially the same approach.¹² KATP is roughly where Nav1.8 was in 2017-2018. The window to build the post-CGRP migraine company is open now.

References

  1. GBD 2021 Nervous System Disorders Collaborators. Lancet Neurol 2024
  2. Steiner TJ et al. J Headache Pain 2020
  3. Vo PT et al. BMC Public Health 2024
  4. Vernieri F et al. Neurology 2023
  5. Kaltseis K et al. BMC Neurology 2023
  6. Al-Karagholi MM. Front Mol Neurosci 2023
  7. Al-Karagholi MM et al. Brain 2019
  8. Kokoti L et al. Cephalalgia 2024
  9. Christensen SL et al. Cephalalgia 2022
  10. Li Ket al. Mol Pharmacol 2024.
  11. Wang M, Wu JX, Ding D, Chen L. Nat Commun 2022
  12. Vertex Pharmaceuticals. Journavx (suzetrigine) FDA approval announcement, January 30, 2025.